Kassem NM, EL Zawam H, Kassem HA, EL Nahas T, El Husseiny NM, Abd El Azeeim H. A descriptive study of plasma cell dyscrasias in Egyptian population. J Egypt Natl Cancer Inst. 2014;26:67–71.
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911–20.
Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019;12:4075–80.
Abd El Kader Y, Emera G, Safwat E, Kassem H, Kassem N. The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. J Egypt Natl Cancer Inst. 2013;25:37–41.
Hashem AM, Fahmy HM, Abdo ES, et al. Prevalence of occult hepatitis C virus infection in patients with multiple myeloma. Med J Cairo Univ. 2015;83:507–13.
Bird SA, Boyd K. Multiple myeloma: an overview of management. Palli Care Social Practice. 2019;13:1–13.
Globocan 2018. https://gco.iarc.fr/today/data/factsheets/populations/818-egypt-fact-sheets.pdf.
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.
El-Ghitany EM. Hepatitis C virus infection in Egypt: current situation and future perspective. J High Inst Public Health. 2019;49(1):1–9.
Talima S, Kassem H, Kassem N. Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection. Breast Cancer. 2019;26:154–63.
Li Y, Li Y, Zhang L, Li W. Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies. J Viral Hepat. 2017;24:1151–9.
Farawela H, Khorshied M, Shaheen I, Gouda H, Nasef A, Abulata N, et al. The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin’s lymphoma risk in Egypt. Infect Genet Evol. 2012 Aug;12(6):1189–94.
Teng CJ, Liu HT, Liu CY, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics (Sao Paulo, Brazil). 2011;66:2055–61.
McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051–60.
Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–58.
Cavanna L, Sbolli G, Tanzi E, Romanò L, Civardi G, Buscarini E, et al. High prevalence of antibodies to hepatitis C virus in patients with lymphoproliferative disorders. Haematologica. 1995;80:486–7.
Musto P, Dell’Olio M, Carotenuto M, Mangia A, Andriulli A. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood. 1996;88:752–4.
Takeshita M, Sakai H, Okamura S, Higaki K, Oshiro Y, Uike N, et al. Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan. Histopathology. 2006;48:189–98.
Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood. 1996;87:4296–301.
Veneri D, Franchini M, Zanotti R, Frattini F, Randon F, Rinaldi M, et al. Prevalence of hepatitis C virus infection among patients with lymphoproliferative disorders: a single center survey. Am J Hematol. 2007;82:1031.
Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomark Prev. 2008;17:3069–75.
Okan V, Yilmaz M, Bayram A, Kis C, Cifci S, Buyukhatipoglu H, et al. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders. Int J Hematol. 2008;88:403–8.
De Rosa G, Gobbo ML, De Renzo A, Notaro R, Garofalo S, Grimaldi M, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55:77–82.
Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745–52.
Dai B, Chen AY, Corkum CP, et al. Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene. 2016;35:2979–90.
Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infec Dis. 2016;3:ofv211.
Henry SD, Metselaar HJ, Van Dijck J, Tilanus HW, Van Der Laan LJ. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci. 2007;1110:439–47.
Rance E, Tanner JE, Alfieri C. Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication. J Viral Hepat. 2012;19:e73–80.
Mahale P, Okhuysen PC, Torres HA. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol. 2014;12:e1.